Log in

Shockwave Medical Stock Forecast, Price & News

+1.55 (+2.24 %)
(As of 09/17/2020 12:00 AM ET)
Today's Range
Now: $70.70
50-Day Range
MA: $58.21
52-Week Range
Now: $70.70
Volume740,712 shs
Average Volume455,979 shs
Market Capitalization$2.40 billion
P/E RatioN/A
Dividend YieldN/A
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:SWAV



Sales & Book Value

Annual Sales$42.93 million
Book Value$6.81 per share


Net Income$-51,110,000.00
Net Margins-126.34%


Market Cap$2.40 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
+1.55 (+2.24 %)
(As of 09/17/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SWAV News and Ratings via Email

Sign-up to receive the latest news and ratings for SWAV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Shockwave Medical (NASDAQ:SWAV) Frequently Asked Questions

How has Shockwave Medical's stock been impacted by COVID-19?

Shockwave Medical's stock was trading at $34.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SWAV shares have increased by 105.3% and is now trading at $70.70.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Shockwave Medical?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shockwave Medical in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Shockwave Medical

When is Shockwave Medical's next earnings date?

Shockwave Medical is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Shockwave Medical

How were Shockwave Medical's earnings last quarter?

Shockwave Medical Inc (NASDAQ:SWAV) issued its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.56) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.62) by $0.06. The firm had revenue of $10.30 million for the quarter, compared to analysts' expectations of $8.35 million. Shockwave Medical had a negative return on equity of 35.68% and a negative net margin of 126.34%. Shockwave Medical's quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.38) EPS.
View Shockwave Medical's earnings history

What price target have analysts set for SWAV?

7 equities research analysts have issued 12 month price objectives for Shockwave Medical's stock. Their forecasts range from $23.00 to $76.00. On average, they expect Shockwave Medical's stock price to reach $50.86 in the next year. This suggests that the stock has a possible downside of 28.1%.
View analysts' price targets for Shockwave Medical

Are investors shorting Shockwave Medical?

Shockwave Medical saw a drop in short interest in August. As of August 14th, there was short interest totaling 3,390,000 shares, a drop of 14.4% from the July 30th total of 3,960,000 shares. Based on an average trading volume of 416,500 shares, the days-to-cover ratio is currently 8.1 days. Currently, 12.7% of the shares of the stock are sold short.
View Shockwave Medical's Short Interest

Who are some of Shockwave Medical's key competitors?

What other stocks do shareholders of Shockwave Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shockwave Medical investors own include NVIDIA (NVDA), salesforce.com (CRM), Trade Desk (TTD), Walt Disney (DIS), Square (SQ), Paypal (PYPL), Roku (ROKU), Alibaba Group (BABA), Shopify (SHOP) and Okta (OKTA).

Who are Shockwave Medical's key executives?

Shockwave Medical's management team includes the following people:
  • Mr. Douglas E. Godshall, CEO, Pres & Director (Age 54)
  • Mr. Daniel Puckett, CFO & Sec. (Age 55)
  • Mr. Isaac Zacharias, Chief Commercial Officer (Age 44)
  • Mr. Daniel Hawkins, Founder and Sr. Advisor (Age 52)
  • Mr. John M. Adams, Co-Founder and Technical Advisor (Age 72)

When did Shockwave Medical IPO?

(SWAV) raised $75 million in an initial public offering (IPO) on Thursday, March 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is Shockwave Medical's stock symbol?

Shockwave Medical trades on the NASDAQ under the ticker symbol "SWAV."

Who are Shockwave Medical's major shareholders?

Shockwave Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (14.90%), Vanguard Group Inc. (6.29%), Gilder Gagnon Howe & Co. LLC (6.01%), Jennison Associates LLC (1.82%), Macquarie Group Ltd. (1.75%) and Bellevue Group AG (1.31%). Company insiders that own Shockwave Medical stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frederic H Moll, Isaac Zacharias, James E Flynn and Sofinnova Capital Vii Fcpr.
View institutional ownership trends for Shockwave Medical

Which institutional investors are selling Shockwave Medical stock?

SWAV stock was sold by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., California Public Employees Retirement System, Prudential Financial Inc., Cypress Capital Management LLC WY, US Bancorp DE, and Private Advisor Group LLC. Company insiders that have sold Shockwave Medical company stock in the last year include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frederic H Moll, Isaac Zacharias, and Sofinnova Capital Vii Fcpr.
View insider buying and selling activity for Shockwave Medical

Which institutional investors are buying Shockwave Medical stock?

SWAV stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Gilder Gagnon Howe & Co. LLC, FMR LLC, Vanguard Group Inc., Point72 Asset Management L.P., Goldman Sachs Group Inc., Bellevue Group AG, and Rhenman & Partners Asset Management AB.
View insider buying and selling activity for Shockwave Medical

How do I buy shares of Shockwave Medical?

Shares of SWAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Shockwave Medical's stock price today?

One share of SWAV stock can currently be purchased for approximately $70.70.

How big of a company is Shockwave Medical?

Shockwave Medical has a market capitalization of $2.40 billion and generates $42.93 million in revenue each year. The company earns $-51,110,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Shockwave Medical employs 162 workers across the globe.

What is Shockwave Medical's official website?

The official website for Shockwave Medical is www.shockwavemedical.com.

How can I contact Shockwave Medical?

Shockwave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The company can be reached via phone at 510-279-4262 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.